AILERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.69 USD | -2.12% |
|
-4.90% | +21.04% |
| May. 03 | Aileron Therapeutics Closes Direct Offering of Shares, Warrants | MT |
| May. 01 | Transcript : Aileron Therapeutics, Inc. - Special Call |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15.94 | 42.31 | 50.98 | 10.76 | 14.89 | 78.01 | - | - |
| Enterprise Value (EV) 1 | 15.94 | 42.31 | 50.98 | 10.76 | 14.89 | 78.01 | 78.01 | 78.01 |
| P/E ratio | -0.48 x | -1.7 x | -1.94 x | -0.39 x | -0.89 x | -1.02 x | -2.04 x | -2.93 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | -534,724 x | -2,080,953 x | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,391 | 2,034 | 4,529 | 4,541 | 4,886 | 21,142 | - | - |
| Reference price 2 | 11.46 | 20.80 | 11.26 | 2.370 | 3.049 | 3.690 | 3.690 | 3.690 |
| Announcement Date | 3/30/20 | 3/24/21 | 3/28/22 | 3/20/23 | 4/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | -29.8 | -20.33 | - | - | - | - | - | - |
| EBIT 1 | -29.96 | -20.5 | -26.6 | -27.65 | -16.28 | -23.48 | -27.67 | -32.57 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -29.37 | -21.16 | -26.16 | -27.33 | -15.73 | -23.06 | -26.96 | -31.37 |
| Net income 1 | -29.37 | -21.16 | -26.16 | -27.33 | -15.73 | -23.06 | -26.96 | -31.37 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -24.00 | -12.20 | -5.800 | -6.020 | -3.420 | -3.620 | -1.810 | -1.260 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/24/21 | 3/28/22 | 3/20/23 | 4/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.816 | -8.421 | -8.041 | -6.482 | -4.703 | -5.011 | -2.08 | -7.29 | -7.205 | -5.548 | -6.173 | -6.741 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.799 | -8.422 | -7.992 | -6.368 | -4.547 | -4.779 | -1.787 | -7.339 | -7.113 | -5.548 | -6.072 | -6.416 |
| Net income 1 | -6.799 | -8.422 | -7.992 | -6.368 | -4.547 | -4.779 | -1.787 | -7.339 | -7.113 | -5.548 | -6.072 | -6.416 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.600 | -1.800 | -1.800 | -1.400 | -1.020 | -1.050 | -0.3900 | -1.540 | -0.8600 | -1.130 | -0.8200 | -0.6500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/5/22 | 8/15/22 | 11/1/22 | 3/20/23 | 5/8/23 | 8/11/23 | 4/15/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.15 | 0.01 | 0.16 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/24/21 | 3/28/22 | 3/20/23 | 4/15/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.69
USD
Average target price
19
USD
Spread / Average Target
+414.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.04% | 78.01M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -12.38% | 22.31B | |
| -3.20% | 21.6B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B | |
| -24.50% | 8.28B |
- Stock Market
- Equities
- ALRN Stock
- Financials Aileron Therapeutics, Inc.